Abstract
A third of patients with non-small cell lung cancer (NSCLC) present with unresectable stage III locally advanced disease and are currently treated by chemo-radiation therapy. The median survival is only about 21 months, emphasizing the need to improve the therapeutic outcomes. We have investigated the combination of radiation therapy with axitinib (AG-013736, Pfizer). Axitinib, an anti-angiogenic drug, is a small molecule receptor tyrosine kinase inhibitor, which selectively targets the signal transduction induced by VEGF binding to VEGFR receptors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
